XRP to $20 By 2030? Expert Shares Price Prediction from 2025 to 2050
Crypto analyst ChartNerd (@ChartNerdTA) recently shared a detailed XRP price forecast, highlighting a clear trajectory for the token over the next three decades. The chart predicts a steady increase from its current trading price of $1.33 to levels that could surpass $100 by 2050.
ChartNerd emphasized that 2026 presents an early opportunity for investors. He believes that once the current bearish phase ends, the asset could begin a record-breaking run.
$XRP $20 by 2030 is close enough to my own $27 targets, so I'll take it. 2026 is, however, offering opportunity before that take-off. Buckle up. Once this bearish phase passes, the next few years will be record-breaking. Mark my words.
— 🇬🇧 ChartNerd 📊 (@ChartNerdTA) March 28, 2026
XRP Targets for the Coming Years
According to the forecast, XRP’s minimum price for 2026 is $4.94, with an average of $5.53, and a maximum of $6.18. While XRP began the year with a surge, it quickly retraced, falling close to $1.1.
However, these figures suggest that the token could double in value from its current price. These levels are much higher than the asset’s peak price of $3.65, with current levels offering a potential entry point for traders looking to position themselves ahead of larger gains.
The trajectory continues upward. By 2027, XRP may reach a minimum of $6.23, with an average of $7.16 and a maximum of $8.71.
In 2028, the projections rise to $8.78 at the minimum, with double-digit targets of $10.29 on average, and $12.84 at the maximum. These early targets indicate a period of consistent growth, setting the stage for more substantial advances as adoption and network activity increase.
Mid-Term Outlook
ChartNerd’s chart indicates that by 2029, XRP could reach $13.06 at the minimum, $15.35 on average, and $16.79 at the maximum. In 2030, the minimum projection is $16.86, the average is $18.34, and the maximum reaches $20.03.
These numbers align closely with his $27 target for 2030. ChartNerd noted, “2026 is, however, offering opportunity before that take-off,” signaling the importance of positioning ahead of accelerated growth.
Long-Term Prospects
Beyond 2030, XRP’s growth is projected to be substantial. By 2035, minimum prices could reach $35.47, with an average of $38.16 and a maximum of $40.29.
The 2040 forecast shows minimum levels at $59.08, an average of $63.86, and a maximum of $71.34. By 2050, the projections are particularly striking, with minimum values at $106.18, an average of $115.43, and a maximum of $128.56.
These figures indicate that XRP could become a dominant asset in the cryptocurrency sector over the next three decades. They suggest that the asset could enjoy both increasing adoption and potential integration into larger financial systems.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
